Literature DB >> 10365152

Resection of pulmonary metastases from renal cell carcinoma.

G Friedel1, M Hürtgen, M Penzenstadler, T Kyriss, H Toomes.   

Abstract

Between 1980 and 1995, 77 patients underwent complete resection of pulmonary metastases from a renal cell carcinoma after exclusion of a primary tumor recurrence and other metastatic localizations. 30-day mortality was 3%. The Median follow-up was 34 months (M). Cumulative 5-year survival (5-YS) was 39%. Prognostic criteria are the duration of the disease-free interval (DFI) and the number of metastases. Patients with a DFI > or = 48 M had a 5-YS of 46% compared to 26% for a DFI of < 48 M. Patients with a solitary metastasis had a 5-YS of 49% compared to 19% for multiple metastases. There was no significant difference in terms of sex, kind of access, kind of operation, and unilateral or bilateral affection. Since metastases from renal cell carcinomas are almost resistant to chemotherapy and radiotherapy and immunotherapy at present does not considerably improve long-term survival, surgical resection currently is the only effective therapeutic access in renal cell cancer metastasized to the lung.

Entities:  

Mesh:

Year:  1999        PMID: 10365152

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

Review 1.  [Metastasectomy for renal cell cancer].

Authors:  B Brehmer; C Piper; D Pfister; D Porres; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 2.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

3.  Characterization of the frequency distribution for human hematogenous metastases: evidence for clustering and a power variance function.

Authors:  W S Kendal; F J Lagerwaard; O Agboola
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

5.  Breast and Axillary Lymph Nodes Metastasis five years after Radical Nephrectomy for Renal Cell Carcinoma A Case Report and Review of the Literature.

Authors:  H Hairulfaizi; M Rohaizak; I Naqiyah; Ml Yahya; Gc Tan; Z Zainuddin
Journal:  Libyan J Med       Date:  2009-09-01       Impact factor: 1.657

6.  Solitary pulmonary metastases from renal cell carcinoma: comparison of high-resolution CT with pathological findings.

Authors:  Masahiro Yanagawa; Keiko Kuriyama; Mitsuhiro Koyama; Masahiko Higashiyama; Yoshitane Tsukamoto; Jun Arisawa; Noriyuki Tomiyama; Hironobu Nakamura
Journal:  Radiat Med       Date:  2006-12-25

7.  Long-term management of patients with metastatic renal cell carcinoma on targeted agents.

Authors:  Eric Jonasch; Lance C Pagliaro; Nizar M Tannir
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

8.  Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience.

Authors:  Atsunari Kawashima; Masashi Nakayama; Daizo Oka; Mototaka Sato; Koji Hatano; Masatoshi Mukai; Akira Nagahara; Yasutomo Nakai; Hitoshi Takayama; Masayoshi Inoue; Hiroyuki Shiono; Kazuo Nishimura; Meinoshin Okumura; Norio Nonomura
Journal:  Int J Clin Oncol       Date:  2011-05-10       Impact factor: 3.402

Review 9.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

10.  [Surgical treatment of pulmonary metastases from renal cancer].

Authors:  S Piltz; G Meimarakis; M Wichmann; R Oberneder; K-W Jauch; H Fürst
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.